Global Community

1. Catalysts Evenamide (Schizophrenia Add-On Therapy): The key growth catalyst for Newron is Evenamide, a novel glutamate-modulating drug in Phase III development for treatment-resistant schizophrenia (TRS).Read more

DFC based on: Date: August 28, 2025 Forecast Horizon : 5.0 years ## Weighted Average Cost of Capital (WACC) - WACC Value : 0.0296 - Calculation Details : - Equity Market Value : 251,279,184.0 - Debt Market Value : 1,468,357.0 - Total Capital : 252,747,541.0 - Cost of Equity (CAPM) : 0.0292 - Cost of Debt : 0.1276 - Tax Rate : 30.95% ## Capital Asset Pricing Model (CAPM) - Risk-Free Rate : 0.0180 - Beta : 0.41 - Equity Risk Premium (ERP) : 0.0274 - CAPM Formula : Risk-free rate + Beta × ERP - CAPM Value : 0.0292 ## Cost of Debt - Interest Expense : 187,409.0 - Debt Market Value : 1,468,357.0 - Cost of Debt Formula : Interest Expense / Debt Market Value - Cost of Debt Value : 0.1276 ## Growth Model Analysis - Initial Growth Rate : 27.02% - Number of Periods (n) : 5.0 - Terminal Growth Rate : 2.00% ## WACC Data Table | Metric | Value | |:---------------------|-----------------:| | initial FCFF | 1.46232e+07 | | initial growth rate | 0.270176 | | equity market value | 2.51279e+08 | | debt market value | 1.46836e+06 | | tax rate | 0.309485 | | Risk-free rate | 0.018 | | beta | 0.41 | | ERP | 0.0274349 | | terminal growth rate | 0.02 | | forecast horizon | 5 | | Interest expense | 187409 | | number of shares | 4.05289e+08 | ## DCF Fair Value Estimate - Estimated Fair Bear Value: 6.107 - Estimated Fair Base Value: 7.499 - Estimated Fair Bull Value: 11.320 - Expected Value of PERT Distribution: 7.904Read more

Hipages appears to be at a significant turning point, showing strong signs of operational and financial health after a period of strategic change. The key takeaway from the FY25 results is the successful execution of its transition from a simple marketplace to a more integrated Software-as-a-Service (SaaS) platform, which is now yielding positive results.Read more

Catalysts AL001 : a novel lithium formulation targeting Alzheimer's disease, Bipolar Disorder, Major Depressive Disorder (MDD), and PTSD. Phase II studies show promising safety/efficacy, with trials ongoing as of 2025.Read more

The Company Freightos is a International SaaS-like company that operates a B2B platform for booking logistics services. Freightos consists of two divisions: Freightos for shipping & Webcargo for air logistics, where revenue is generated through transaction fees as well as the use of the platform directly through page subscriptions.Read more

My Analysis & Fair Value Projection 1. Fundamentals DMCI is a highly diversified conglomerate: construction, mining, energy, real estate, water, and manufacturing .Read more

Watching Figma Grow Up I’ve been using Figma almost every single day for the past five years. As a product designer, it’s been my main tool for designing interfaces, testing and prototyping ideas, and also for working together with teams in different countries and time zones.Read more

The company just announced that investors have agreed to suscribe an increase of capital to raise USD 35M, at a price of SEK 16. The USD 35 M, i believe is the current free float of the company so I understand this investor can not invest the ammount they want unless a capital raise is made.Read more

Commonly, public misconceptions mislead the market to poorly represent a company's true worth. The saying says "if it sounds too good to be true, it's most likely not true" rings in my ear when evaluating the future of NVIDIA.Read more